A Trial of Varenicline for E-cigarette Cessation
Key facts
- Who runs it
- Yale University
- Where
- Charleston and New Haven, United StatesSee the 2 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 326 people, planned
- Started
- 14 Oct 2025
- Expected to end
- 30 Oct 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Varenicline 1mg BID
- Placebo
- Record updated
- 17 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- report daily use of an e-cigarette containing nicotine
- live in Connecticut or South Carolina
Who cannot take part
- regular use of other tobacco products besides e-cigarettes
- medical contraindications for varenicline use
- current treatment for tobacco cessation
- lack proficiency in English
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- E-cigarette use or vaping or nicotine dependence
This trial is currently available in United States.
- Hollings Cancer Center at MUSC (HCC)Charleston, United StatesContact: Lisa Fucito, PhDTaking people
- Yale Cancer Center, Smilow Cancer Hospital at Yale New HavenNew Haven, United StatesContact: Lisa Fucito, PhDTaking people
About the trial
What the trial wants to find out
This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.
The 2 groups in the trial
- VareniclineTreatment being tested
Participants will randomly be assigned to 12-weeks of varenicline (titrated to 2mg daily) plus brief cessation advice with a counselor and self-management resources.
Treatment: Varenicline 1mg BID
- PlaceboPlacebo, for comparison
Participants will randomly be assigned to 12-weeks of matching placebo plus brief cessation advice with a counselor and self-management resources.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Investigating Efficacious E-Cigarette Interventions and Cessation Effects on Cancer-Related Biomarkers: A Randomized Trial of Varenicline in Adults
- Criteria questions
- Built from NCT07040566, who can take part
- Record updated
- 17 December 2025